• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base





    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University







  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base





    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+



      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University


Archive for March, 2016

University of Manchester research to pioneer next generation of skin treatments

IP based on translational research led by Dr Catherine O’Neill and Professor Andrew McBain at The University of Manchester has been transferred into a new company. The venture, Skinbiotix limited, is being supported by OptiBiotix Health plc (AIM: OPTI). OptiBiotix is a leading life sciences business developing products to tackle obesity, high cholesterol and diabetes on a global scale. The agreement was negotiated on behalf of the University by its technology transfer office, UMIP.

Dr O’Neill and Professor McBain will continue to actively support the development of the technology. The company is built on ground-breaking discoveries on the human microbiome and its application to develop skin heath products. It will help create new product opportunities in large global markets including skincare, Health Care Acquired Infections and wound care.

Dr Catherine O’Neil, Senior Lecturer in Clinical Biochemistry at The Centre for Dermatological Research at the University commented: ”The agreement with OptiBiotix is a really important step for our research. There is huge potential that our technology will help create products that will have real impact on the treatment  of skin conditions. “

Stephen O’Hara, OptiBiotix’s Chief Executive Officer, commented: “We are pleased to announce the acquisition of skin health technology from The University of Manchester. This acquisition accelerates OptiBiotix’s strategic intent to grow the company by extending our platform technologies into new application areas where there are large global markets and an unmet need. We expect this venture will lead to new product and partnering opportunities and make a significant contribution to the Group over the coming years.”

Director of Operations at UMIP, Dr. Rich Ferrie commented, “We are delighted to have entered into this agreement with OptiBiotix, who we believe is the ideal partner to develop the ground-breaking skin health microbiome science developed by Dr Catherine O’Neill and Professor Andrew McBain. The signing of this agreement represents a pivotal moment towards the release of innovative and effective skin healthcare products.”

Untreated

Untreated

treated

Treated

 

The images show human skin which has been stained with a green dye to visualise a protein, critical to skins function as a barrier between the body and the environment. The level of this protein increases dramatically following treatment with a particular bacterium (compare ‘untreated’ with ‘treated’).

 

 

MMPathIC: Engaging Engineers and Physical Scientists

The Manchester Molecular Pathology Innovation Centre (MMPathIC) is co-funded by the Engineering and Physical Sciences Research Council, as both EPSRC and the MRC recognise the key role that the EPS disciplines will need to play to develop the next generation of diagnostics and molecular pathology tests. To kick start this necessary engagement, this workshop will bring together clinicians, biologists, engineers and physical scientists, to examine the hurdles that may need to be overcome for effective inter-disciplinary working to achieve MMPathICs objective to get new tests to the clinic or market. Additionally, this workshop will also be an opportunity to inform/ influence the pump-priming flexible fund which is encompassed within the node’s activities, and for which UoM academics and MAHSC clinicians will be able to compete.

You are invited to this Facilitated workshop

Share your expertise, experiences, interests, successes and failures at this workshop with like-minded individuals?

Time for networking and informal discussion….starting with lunch at 12:00 and finishing at ~17:00 (exact timings TBC) with a coffee/tea break in the afternoon.

Further details on the flexible funding pot (which comprises Workstrand 6 “Innovation and Technologies” of the MMPathIC bid, led by Professor Roy Goodacre) which will pump prime novel interdisciplinary projects will be presented. The event will be an opportunity to influence the criteria around how this funding is allocated.

WHERE:  Kanaris Lecture Theatre @ Manchester Museum

WHEN:    14 April (12:00 until ~17:00)

WHAT:    Engineering/Physical Sciences Workshop

For further details, contact Dr. Katherine Boylan (Katherine.boylan@manchester.ac.uk) or Dr. Penny Johnson (Penny.johnson-2@manchester.ac.uk)

If you are interested in attending, please register here-

https://www.eventbrite.co.uk/e/mmpathic-engaging-engineers-and-physical-scientists-tickets-22171014100

CONTACT US